12/3
04:33 pm
scnx
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
08:17 am
scnx
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 [Yahoo! Finance]
Low
Report
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 [Yahoo! Finance]
12/2
08:05 am
scnx
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
Low
Report
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
11/27
02:53 pm
scnx
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
08:38 am
scnx
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/13
08:05 am
scnx
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
Medium
Report
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
11/4
08:05 am
scnx
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
Low
Report
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
10/23
08:05 am
scnx
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
High
Report
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
10/16
09:00 am
scnx
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
High
Report
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
10/13
08:20 am
scnx
Wellgistics Health Announces Executive Management and Board Changes [Yahoo! Finance]
Medium
Report
Wellgistics Health Announces Executive Management and Board Changes [Yahoo! Finance]
10/13
08:15 am
scnx
Wellgistics Health reappoints Prashant Patel as interim CEO amid executive shakeup [Seeking Alpha]
Medium
Report
Wellgistics Health reappoints Prashant Patel as interim CEO amid executive shakeup [Seeking Alpha]
10/8
09:00 am
scnx
SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
Medium
Report
SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
10/1
09:00 am
scnx
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
High
Report
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
10/1
08:53 am
scnx
EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions [Yahoo! Finance]
Medium
Report
EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions [Yahoo! Finance]
9/16
08:05 am
scnx
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
High
Report
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market